Literature DB >> 15082091

High carbohydrate diets and Alzheimer's disease.

Samuel T Henderson1.   

Abstract

Alzheimer's disease (AD) is a common, progressive, neurodegenerative disease that primarily afflicts the elderly. A well-defined risk factor for late onset AD is possession of one or more alleles of the epsilon-4 variant (E4) of the apolipoprotein E gene. Meta-analysis of allele frequencies has found that E4 is rare in populations with long historical exposure to agriculture, suggesting that consumption of a high carbohydrate (HC) diet may have selected against E4 carriers. The apoE4 protein alters lipid metabolism in a manner similar to a HC diet, suggesting a common mechanism for the etiology of AD. Evolutionarily discordant HC diets are proposed to be the primary cause of AD by two general mechanisms. (1) Disturbances in lipid metabolism within the central nervous system inhibits the function of membrane proteins such as glucose transporters and the amyloid precursor protein. (2) Prolonged excessive insulin/IGF signaling accelerates cellular damage in cerebral neurons. These two factors ultimately lead to the clinical and pathological course of AD. This hypothesis also suggests several preventative and treatment strategies. A change in diet emphasizing decreasing dietary carbohydrates and increasing essential fatty acids (EFA) may effectively prevent AD. Interventions that restore lipid homeostasis may treat the disease, including drugs that increase fatty acid metabolism, EFA repletion therapy, and ketone body treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15082091     DOI: 10.1016/j.mehy.2003.11.028

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  19 in total

Review 1.  Neuroprotective and disease-modifying effects of the ketogenic diet.

Authors:  Maciej Gasior; Michael A Rogawski; Adam L Hartman
Journal:  Behav Pharmacol       Date:  2006-09       Impact factor: 2.293

Review 2.  Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal.

Authors:  Ramesh Kandimalla; Vani Thirumala; P Hemachandra Reddy
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2016-08-25       Impact factor: 5.187

Review 3.  Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease.

Authors:  Therese S Salameh; Elizabeth M Rhea; William A Banks; Angela J Hanson
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-28

4.  Silymarin ameliorates memory deficits and neuropathological changes in mouse model of high-fat-diet-induced experimental dementia.

Authors:  Amit Kumar; Amteshwar S Jaggi; Rupinder K Sodhi; Nirmal Singh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-05-28       Impact factor: 3.000

5.  The ketogenic diet: uses in epilepsy and other neurologic illnesses.

Authors:  Kristin W Barañano; Adam L Hartman
Journal:  Curr Treat Options Neurol       Date:  2008-11       Impact factor: 3.598

6.  Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  Samuel T Henderson; Janet L Vogel; Linda J Barr; Fiona Garvin; Julie J Jones; Lauren C Costantini
Journal:  Nutr Metab (Lond)       Date:  2009-08-10       Impact factor: 4.169

Review 7.  Ketone bodies as a therapeutic for Alzheimer's disease.

Authors:  Samuel T Henderson
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

Review 8.  Metabolic disorder in Alzheimer's disease.

Authors:  Mrinal K Poddar; Soumyabrata Banerjee; Apala Chakraborty; Debasmita Dutta
Journal:  Metab Brain Dis       Date:  2021-02-27       Impact factor: 3.584

9.  Precision Nutrition for Alzheimer's Prevention in ApoE4 Carriers.

Authors:  Nicholas G Norwitz; Nabeel Saif; Ingrid Estrada Ariza; Richard S Isaacson
Journal:  Nutrients       Date:  2021-04-19       Impact factor: 5.717

Review 10.  Hypometabolism as a therapeutic target in Alzheimer's disease.

Authors:  Lauren C Costantini; Linda J Barr; Janet L Vogel; Samuel T Henderson
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.